TY - JOUR
T1 - Identification of phenotypes in paediatric patients with acute respiratory distress syndrome
T2 - a latent class analysis
AU - RESTORE and BALI study investigators
AU - Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network
AU - Dahmer, Mary K.
AU - Yang, Guangyu
AU - Zhang, Min
AU - Quasney, Michael W.
AU - Sapru, Anil
AU - Weeks, Heidi M.
AU - Sinha, Pratik
AU - Curley, Martha A.Q.
AU - Delucchi, Kevin L.
AU - Calfee, Carolyn S.
AU - Flori, Heidi
AU - Matthay, Michael A.
AU - Bateman, Scot T.
AU - Berg, Marc D.
AU - Borasino, Santiago
AU - Bysani, Gokul K.
AU - Cowl, Allison S.
AU - Bowens, Cindy D.
AU - Faustino, Vincent S.
AU - Fineman, Lori D.
AU - Godshall, Aaron J.
AU - Hirshberg, Eliotte L.
AU - Kirby, Aileen L.
AU - McLaughlin, Gwenn E.
AU - Medar, Shivanand S.
AU - Oren, Phineas P.
AU - Schneider, James B.
AU - Schwarz, Adam J.
AU - Shanley, Thomas P.
AU - Source, Lauren R.
AU - Truemper, Edward J.
AU - Vender Heyden, Michele A.
AU - Wittmayer, Kimberly
AU - Zuppa, Athena F.
AU - Wypij, David
N1 - Funding Information:
We thank all patients who participated in the trial and their parents or guardians. Additionally, we thank all the individuals who supported the RESTORE and BALI studies at participating institutions and the RESTORE Data Coordinating Centre. This study was supported by funding from the National Institutes of Health; U01 HL086622 (awarded to MAQC) funded the RESTORE clinical trial from which the patients in this secondary analysis were derived; R01 HL095410 (awarded to MWQ, HF, and MKD) funded the ancillary BALI trial, which enabled plasma samples to be obtained from a subset of patients enrolled in RESTORE; R21 HD097387 (awarded to MKD and HF) funded the latent class analysis described in this paper. CSC was funded by an individual grant from the National Institutes of Health (R35 HL140026).
Funding Information:
MKD, MZ, MAQC, AS, KLD, and HF report grants from the US National Institutes of Health. CSC reports grants from the US National Institutes of Health, Roche/Genentech, Bayer, and Quantum Leap Healthcare Collaborative; and consultancy fees from Quark Pharmaceuticals, Prometic, Gen1e Life Sciences, and Vasomune. MWQ reports consultancy fees from Mitchell Leeds, Tanoury, Nauts, and McKinney and Barbarino. All other authors declare no competing interests.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/3
Y1 - 2022/3
N2 - Background: Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflammation. We aimed to identify phenotypes in children with ARDS in whom developmental differences might be important, using a latent class analysis approach similar to that used in adults. Methods: This study was a secondary analysis of data aggregated from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial and the Genetic Variation and Biomarkers in Children with Acute Lung Injury (BALI) ancillary study. We used latent class analysis, which included demographic, clinical, and plasma biomarker variables, to identify paediatric ARDS (PARDS) phenotypes within a cohort of children included in the RESTORE and BALI studies. The association of phenotypes with clinically relevant outcomes and the performance of paediatric data in adult ARDS classification algorithms were also assessed. Findings: 304 children with PARDS were included in this secondary analysis. Using latent class analysis, a two-class model was a better fit for the cohort than a one-class model (p<0·001). Latent class analysis identified two classes: class 1 (181 [60%] of 304 patients with PARDS) and class 2 (123 [40%] of 304 patients with PARDS), referred to as phenotype 1 and 2 hereafter. Phenotype 2 was characterised by higher concentrations of inflammatory biomarkers, a higher incidence of vasopressor use, and more frequent diagnosis of sepsis, consistent with the adult hyperinflammatory phenotype. All levels of severity of PARDS were observed across both phenotypes. Children with the hyperinflammatory phenotype (phenotype 2) had worse clinical outcomes than those with the hypoinflammatory phenotype (phenotype 1), with a longer duration of mechanical ventilation (median 10·0 days [IQR 6·3–21·0] for phenotype 2 vs 6·6 days [4·1–10·8] for phenotype 1, p<0·0001), and higher incidence of mortality (17 [13·8%] of 123 patients vs four [2·2%] of 181 patients, p=0·0001). When using adult phenotype classification algorithms in children, the soluble tumour necrosis factor receptor-1 (sTNFr1), vasopressor use, and interleukin (IL)-6 variables gave an area under the curve (AUC) of 0·956, and the sTNFr1, vasopressor use, and IL-8 variables gave an AUC of 0·954, compared with the gold standard of latent class analysis. Interpretation: Latent class analysis identified two phenotypes in children with ARDS with characteristics similar to those in adults, including worse outcomes among patients with the hyperinflammatory phenotype. PARDS phenotypes should be considered in design and analysis of future clinical trials in children. Funding: US National Institutes of Health.
AB - Background: Previous latent class analysis of adults with acute respiratory distress syndrome (ARDS) identified two phenotypes, distinguished by the degree of inflammation. We aimed to identify phenotypes in children with ARDS in whom developmental differences might be important, using a latent class analysis approach similar to that used in adults. Methods: This study was a secondary analysis of data aggregated from the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) clinical trial and the Genetic Variation and Biomarkers in Children with Acute Lung Injury (BALI) ancillary study. We used latent class analysis, which included demographic, clinical, and plasma biomarker variables, to identify paediatric ARDS (PARDS) phenotypes within a cohort of children included in the RESTORE and BALI studies. The association of phenotypes with clinically relevant outcomes and the performance of paediatric data in adult ARDS classification algorithms were also assessed. Findings: 304 children with PARDS were included in this secondary analysis. Using latent class analysis, a two-class model was a better fit for the cohort than a one-class model (p<0·001). Latent class analysis identified two classes: class 1 (181 [60%] of 304 patients with PARDS) and class 2 (123 [40%] of 304 patients with PARDS), referred to as phenotype 1 and 2 hereafter. Phenotype 2 was characterised by higher concentrations of inflammatory biomarkers, a higher incidence of vasopressor use, and more frequent diagnosis of sepsis, consistent with the adult hyperinflammatory phenotype. All levels of severity of PARDS were observed across both phenotypes. Children with the hyperinflammatory phenotype (phenotype 2) had worse clinical outcomes than those with the hypoinflammatory phenotype (phenotype 1), with a longer duration of mechanical ventilation (median 10·0 days [IQR 6·3–21·0] for phenotype 2 vs 6·6 days [4·1–10·8] for phenotype 1, p<0·0001), and higher incidence of mortality (17 [13·8%] of 123 patients vs four [2·2%] of 181 patients, p=0·0001). When using adult phenotype classification algorithms in children, the soluble tumour necrosis factor receptor-1 (sTNFr1), vasopressor use, and interleukin (IL)-6 variables gave an area under the curve (AUC) of 0·956, and the sTNFr1, vasopressor use, and IL-8 variables gave an AUC of 0·954, compared with the gold standard of latent class analysis. Interpretation: Latent class analysis identified two phenotypes in children with ARDS with characteristics similar to those in adults, including worse outcomes among patients with the hyperinflammatory phenotype. PARDS phenotypes should be considered in design and analysis of future clinical trials in children. Funding: US National Institutes of Health.
UR - http://www.scopus.com/inward/record.url?scp=85122955770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122955770&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(21)00382-9
DO - 10.1016/S2213-2600(21)00382-9
M3 - Article
C2 - 34883088
AN - SCOPUS:85122955770
SN - 2213-2600
VL - 10
SP - 289
EP - 297
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 3
ER -